Such high-affinity TCR should also function in CD8-negative cells such as Th1 or Th17, providing additional support for the anti-tumor response (Cohen et al., 2005; Kuball et al., 2005; Udyavar et al., 2009). Here, CD8A is linked to neoplasm.